<DOC>
	<DOCNO>NCT01925118</DOCNO>
	<brief_summary>Partially HLA-matched irradiate donor lymphcyte infusion alone result 27 % overall response rate ( ORR ) advance renal cell carcinoma without significant toxicity . In addition , high-dose interleukin-2 ( IL-2 ) show ORR 6-21 % metastatic melanoma renal cell carcinoma durable response patient achieve complete remission . Therefore , irradiate donor lymphocyte infusion plus high-dose IL-2 might show synergistic anti-tumor activity agaist relapse metastatic melanoma renal cell carcinoma .</brief_summary>
	<brief_title>Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Histologically confirm malignant melanoma renal cell carcinoma At stage IV relapse At least one prior chemotherapy include targeted agent At least one haploidential partially matchedHLA donor ECOG performance status 01 Age 1875 year Measurable lesion Adequate bone marrow , liver , renal function Chemotherapy within 4 week Stem cell transplantation Active CNS metastasis Hypersensitivity IL2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>